How far are we from a cure? A scientific gap analysis
Map the barriers already partly addressed, the unsolved problems, and the evidence needed before durable treatments become broadly available.
By The Diabetes Guide editorial project · Updated 30 Sept 2026
On this page
A gap map of what stands between today and a cure: stop the immune attack, replace cells, protect them, make them last, keep them safe and make them affordable.
Step 1: Many gaps at once
For Type 1 you need to solve autoimmunity, supply, rejection, lifespan, safety and cost.
For example: A bridge with seven missing planks.
Step 2: Different approaches, different limits
Insulin and pumps manage sugar; transplants can restore insulin but may need immune drugs.
For example: A raincoat protects you from rain but does not stop the weather.
Step 3: Type 2
Remission is possible, but relapse is a risk. Better maintenance could help many people even without a cure.
For example: Keeping a garden neat is easier than replanting it every year.
Remember: A “cure in X years” claim would go beyond the evidence.
The full story
Want more? Below is the detailed version with the real science words. It is fine to skip it.
Type 1: several barriers must be addressed
| Barrier | Partial progress | Unfinished work |
|---|---|---|
| Autoimmune injury | Disease modification in selected groups | Durable tolerance with acceptable safety |
| Replacement cells | Donor and manufactured islets can function | Reliable supply and broad benefit |
| Immune rejection | Immunosuppression enables transplantation | Protection without unacceptable systemic risk |
| Long-term survival | Some grafts function for years | Predictable lifelong function |
| Manufacturing | Scalable cell-production approaches | Consistency, purity and quality control |
| Safety | Defined trial monitoring and selected approvals | Rare harms and long-term surveillance |
| Affordability | Increasing technological capability | Equitable delivery at population scale |
Type 1 research: solve several problems together
Preserve. Immune modulation can preserve function or delay progression in selected people.
Read every step in a list
- Preserve. Immune modulation can preserve function or delay progression in selected people.
- Replace. Donor or stem-cell-derived islets can supply insulin-producing cells.
- Protect. Immune rejection and recurrent autoimmunity require durable solutions.
- Scale safely. Long-term safety, reliable manufacturing, cost and access remain essential.
Cure approaches are not interchangeable
Insulin and artificial-pancreas systems manage glucose but do not remove autoimmune disease. Transplantation can restore secretion but may require continuing immunosuppression. Encapsulation, immune cloaking and regeneration remain investigational strategies with distinct failure modes. No reliable year-by-year cure forecast can be derived from these facts. 6
Type 2: the relapse problem
Resistance can improve and secretion can recover in some people, but genetic susceptibility, altered beta-cell reserve and metabolic environment can persist. Sustained remission is possible; permanent elimination of vulnerability is not established by normal HbA1c. Improving maintenance, early intervention and access may have large benefits without a universal cure. 5
What we know, what we strongly suspect, what we don't know yet, and what scientists are trying to solve next.
We know: insulin replacement is lifesaving, modern care improves outcomes, and selected people can achieve remission or insulin independence under specific conditions. We strongly suspect: durable Type 1 restoration will often need coordinated solutions for cells and immunity. We do not know: who will achieve lifelong treatment-free benefit or how to guarantee it safely. Scientists are trying to solve: durable protection, functional replacement, prevention, relapse, equitable access and long-term safety. The second statement is interpretation; the others remain bounded by the cited evidence.
Trace the evidence
Sources and further reading
1.Stem Cell–Derived, Fully Differentiated Islets for Type 1 Diabetes (opens in a new tab)
Reichman et al.; New England Journal of Medicine · 2025 · Early human study
Who was studied, limits and source check
Population: Selected adults with T1D, severe hypoglycemia and impaired awareness
Sample: 14 with ≥12-month follow-up; 12 at full dose
Limitations: Small, uncontrolled interim analysis; required immunosuppression; serious adverse events and deaths occurred. Not a routine cure.
Source checked 2026-09-30. See the original publication for full methods.
2.Survival of Transplanted Allogeneic Beta Cells with No Immunosuppression (opens in a new tab)
Carlsson et al.; New England Journal of Medicine · 2025 · Early human study
Who was studied, limits and source check
Population: One adult with long-standing T1D
Sample: 1 participant; 12-week reported follow-up
Limitations: Single participant, low cell dose and short follow-up. Does not demonstrate generalizable insulin independence.
Source checked 2026-09-30. See the original publication for full methods.
3.FDA accelerated approval: teplizumab in selected recently diagnosed pediatric Stage 3 T1D (opens in a new tab)
US Food and Drug Administration · 2026 · Regulatory
Who was studied, limits and source check
Population: Children aged 8–17 recently diagnosed with Stage 3 T1D
Sample: PROTECT: 328 participants
Limitations: June 12 accelerated approval based on C-peptide preservation, a surrogate. Confirmatory clinical benefit and label conditions matter.
Source checked 2026-09-30. See the original publication for full methods.
4.FDA approves first donor islet cellular therapy for selected adults with T1D (opens in a new tab)
US Food and Drug Administration · 2023 · Regulatory
Who was studied, limits and source check
Population: Adults with T1D and repeated severe hypoglycemia despite intensive management
Sample: 30 in two nonrandomized single-arm studies
Limitations: Selected population, donor constraints and risks of infusion and immunosuppression. Approval does not establish universal cure.
Source checked 2026-09-30. See the original publication for full methods.
5.Definition and Interpretation of Remission in Type 2 Diabetes (opens in a new tab)
Riddle et al.; international consensus group · 2021 · Guideline
Who was studied, limits and source check
Limitations: A consensus definition, not proof of permanent recovery or an instruction to stop medication.
Source checked 2026-09-30. See the original publication for full methods.
6.Diabetes Technology: Standards of Care 2026 (opens in a new tab)
American Diabetes Association · 2026 · Guideline
Who was studied, limits and source check
Limitations: Access, training, device labeling, and safe-use capacity affect applicability.
Source checked 2026-09-30. See the original publication for full methods.
Source checking is an editorial literature check, not independent medical review. This page is for learning. It cannot diagnose you or make a treatment plan. Evidence labels describe the cited claims, not the whole topic.
What does “Preliminary” mean?
Early results. They need to be repeated. Like a first test drive of a new car.
Keep reading
The body
The one-page mental model
Diabetes means there is too much sugar in the blood for too long, because the body does not have enough insulin or cannot use it well.
Type 1
Type 1 diabetes: the complete journey
Type 1 diabetes is usually an autoimmune condition. The body’s defence system harms the beta cells, so less and less insulin is made.
Type 2
Type 2 diabetes: how the system changes
Type 2 diabetes happens when the body’s need for insulin grows and the pancreas cannot keep up, so sugar slowly rises.